Key Insights

Highlights

No notable highlights available yet

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 2 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

2Total
P 1 (2)

Trial Status

Active Not Recruiting1
Recruiting1

Clinical Trials (2)

Showing 2 of 2 trials
NCT06494579Phase 1Active Not RecruitingPrimary

Lamivudine for Solid Tumors

NCT05528341Phase 1RecruitingPrimary

NKG2D-CAR-NK92 Cells Immunotherapy for Solid Tumors

Showing all 2 trials

Research Network

Activity Timeline